IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates

Core Insights - IGC Pharma, Inc. reported a quarterly loss of $0.02 per share, consistent with the Zacks Consensus Estimate, and the same as the loss reported a year ago [1] - The company generated revenues of $0.19 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 56.59%, and down from $0.41 million year-over-year [2] - IGC Pharma's shares have increased approximately 6% since the beginning of the year, underperforming the S&P 500, which gained 14.6% [3] Financial Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [1] - IGC Pharma has topped consensus revenue estimates two times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $0.31 million, and for the current fiscal year, it is -$0.08 on revenues of $1.5 million [7] Market Outlook - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] - The estimate revisions trend for IGC Pharma was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The Medical - Drugs industry, to which IGC Pharma belongs, is currently in the top 34% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]